原發性肝癌：挑戰與展望

《原發性肝癌：挑戰與展望》是2012年4月1日浙江大學出版社出版的圖書，作者是顧健人。

基本介紹

• 中文名：原發性肝癌：挑戰與展望
• 外文名：Primary Liver Cancer:Challenges and Perspectives
• 作者：顧健人
• 出版日期：2012年4月1日
• 語種：簡體中文, 英語
• ISBN：9787308095556
• 出版社：浙江大學出版社
• 頁數：462 頁
• 開本：16 開

內容簡介

《原發性肝癌:挑戰與展望》中，在中國肝癌領域的領先專家意在與讀者分享他們的新概念，實踐和經驗，從實驗室到床上，從人口研究的個案調查，從分子搜尋到臨床實踐，從早期的診斷和治療。《原發性肝癌:挑戰與展望》的目的是為在肝癌和其他癌症的免疫學，流行病學，分子遺傳學，細胞生物學和原發性肝癌的臨床腫瘤學領域的研究人員提供理論知識。

圖書目錄

1 Concepts, Challenges and Perspectives in Cancer Research

1.1 Cancer is a Well-Organized Tissue, Constructing a Specified Cancer Microenvironment

1.1.1 Cancer Associated Stromal Cells

1.1.2 Extracellular Matrix in Tumor

1.1.3 Tumor Acidic Microenvironment

1.2 Heterogeneity of Cancer Cell Population and Cancer Stem Cell Hypothesis

1.2.1 Cancer Stem Cell ttypothesis

1.2.2 Arguments against Cancer Stem Cell Hypothesis

1.3 Cancer is a Systems Disease--A Disease of Systems Dysregulation, Characterized by Abnormal Growth of the Defmed Tissue or Organ

1.3.1 Systemic Regulatory Systems to Control the Host-Cell Homeostasis

1.4 Prospects and Implications

References

2.1 The New Concept ofHepatic Carcinogenesis： Two Levels ofSystemic Dysregulation in the Development ofHepatocellular Carcinoma (HCC)

2.1.1Hypothesis ofTwo Levels ofSystemic Regulation

2.1.2 Evidence ofSystemic Dysregulation ofCancer Development and Progression

2.2 Non-NeuronaINeurotransmitters and Hepatocellular Carcinoma

2.2.1The Cholinergic System in the Development ofHepatocellular Carcinoma

2.2.2 The Adrenergic System and Hepatocarcinogenesis

2.2.3The Glutamatergic System in the Development of Hepatocellular Carcinoma

2.2.4 The GABAergic System in the Development of Hepatocellular Carcinoma

2.3Regulatory Effects ofCholinergic System on Immune Cells andHormone Receptors ofHCC Cells

2.4 Prospects

Acknowledgements

References

3 Genomics ofHepatocellular Carcinoma

3.1 MultistepHepatocarcinogenesis

3.2 Genetic Susceptibility to Hepatocarcinogenesis

3.3 Genetic Alterations in Hepatocarcinogenesis

3.3.1 ChromosomaIAbnormalities

3.3.2 Somatic Mutations

3.3.3 Single Nucleotide Polymorphis

3.4 Epigenetic Alterations in HCC

3.5 MicroRNA and Hepatocarcinogenesis

3.6 Expression Profiling of HCC

3.7 Signaling Pathways in HCC

3.7.1 Wnup-Catenin Pathway

3.7.2 Ras Signaling Pathway

3.7.3 PI3K/Akt/mTORPathway

3.7.4 DLCl/Rho/ROCK Pathway

3.8 Concluding Remarks and Perspective

Acknowledgements

References

4 Biomarkers ofHepatocellular Carcinoma

4.1Overview ofthe HCC Biomarker Discovery and Development

4.1.1 Development and Evaluation ofBiomarkers for Early Detection/Diagnosis of HCC

4.2 Biomarkers for Early Detection/Diagnosis ofHepatocellular Carcinoma

4.2.1 Alpha-Fetoprotein

4.2.2 Glypican-3

4.2.3 Des-Gamma-Carboxyprothromb

4.2.4 Golgi Phosphoprotein 2

4.2.5 Other Potential Biomarkers for Diagnosis of HCC

4.2.6Combination ofBiomarkers for Diagnosis of HCC

4.2.7 Integrated ""Omics"" Analysis in Searching Biomarkers for Early Detection of HCC

4.3 Biomarkers for Prognosis ofHepatocellular Carcinoma

4.3.1 Tumor-AssociatedAntigens

4.3.2 Cell Cycle-Related Biomarkers

4.3.3Telomerase

4.3.4 Oncogenes and Tumor Suppressor Genes

4.3.5Cellular Adhesion Molecules

4.3.6 Extracellular Matrix Degradation Proteinases

4.3.7Tumor Angiogenesis

4.3.8 Tumor Microenvironment

4.3.9 Combination ofBiomarkers for Prognosis of HCC

4.3.10 Integrated ""Omics"" Analysis in Searching Biomarkers for Prognosis of HCC

4.4 Biomarkers for Molecular Classification and Treatment Selection ofHCC

4.4.1 Biomarkers for Molecular Classification of HCC

4.4.2 Biomarkers for HCC Treatment Selectio

4.5 Outlook

Acknowledgements

References

5 Metabonomics of Hepatocellular Carcinoma

5.1 Analytical Strategy of Metabonomics

5.1.1Collection of Samples

5.1.2 Collection ofMetabonome Data

5.1.3 Multivariate Data Analysis

5.2 Applications ofMetabonomics in Liver Cancer Study

5.2.1Blood, Serum and Bile Metabolic Profiling ofLiver Cancer

5.2.2Urine Metabolic Profiling ofLiver Cancer

5.2.3 Metabonomic Study ofHepatitis B Induced Liver Cirrhosis and Hepatocellular Carcinoma

5.2.4Liver Cancer Investigation Based on Modified Nucleosides in B odyFluids

Acknowledgements

References

6SignaITransduction ofHepatocellular Carcinoma

6.1Overview ofthe Signal Transduction in HCC

6.2 p53 and Rb Signaling Pathways in HCC

6.2.1 p53 Signaling Pathway in HCC

6.2.2 Rb Signaling Pathway in HCC

6.3 Mitogen Activated Protein Kinases Pathway in HCC

6.3.1 Subfamilies ofMAPKs

6.3.2 Common Signaling Pathway ofMAPKs

6.3.3Physiological Functions ofMAPKs

6.3.4 Alterations ofMAPKs in HCC

6.3.5 Other Constitutions ofMAPKs Signaling and their Alterationsin HCC

6.4 Wnt/β-Catenin Pathway in HCC

6.4.1 Wnt/β-Catenin Signaling and its Regulation

6.4.2 Aberrant Activation ofWnt/β-Catenin Signaling in HCC

6.5 Transforming Growth Factor-β Signaling in HCC

6.5.1 TGF-β Signaling Pathway and its Regulation

6.5.2 TGF-β Signaling in Different Stages ofHCC

6.6 Nuclear Factor-κB Pathway in HCC

6.6.1 Complex NF-κB Signaling SyOtem

6.6.2 Contradictory Effects ofNF-κB Activation onHepatocarcinogenesis

6.7 PI3K/Akt/mTOR Pathway in HCC

6.7.1 PI3K/Akt/mTOR Signaling andits Regulation

6.7.2 PI3K/Akt/mTOR Signalingin HCC

6.8 Other Pathways Associated with HCC

6.8.1 The JAK/STAT Pathwayin HCC

6.8.2 Hedgehog Signaling Pathway

6.8.3 Notch Signaling Pathway

6.8.4Stem Cell Related Signaling Pathways in HCC

6.9Molecular Targets for Therapy in HCC

6.9.1 Growth Factors-MAPK Pathway-Based Strategies

6.9.2 NF-KB-basedStrategies

6.9.3 PI3K/Akt/mTORPathway-BasedStrategies

6.9.4Other Targets for Therapy in HCC

Acknowledgements

References

7 Cancer Stem Cells ofHepatocellular Carcinoma

7 .1Introduction

7.2 Cancer Stem CelIHypothesis

7.3Identification ofHCC Stem Cells with Potential Stem Cell Markers

7.3.1 CD133+,CD133+/CD44+Cells

7.3.2 EpCAM+Cells

7.3.3 CD90+ Cells

7.3.4 OV6+ Cells

7.4 SP Cells ofHepatocellular Carcinoma

7.5Challenges to Cancer Stem Cell Hypothesis

7.6Clinical Impacts and Perspectives

7.7Conclusions

References

……

8 Immunology of Liver

9 Immunosuppresssioa and Immune Escape in Liver Cancer

10 Immunotherapy of Hepatocellular Carcinoma

11 Chemoprevention of Hepatic Cancer in Aflatoxin Endemic Areas

12 Metastasis of Hepatic Cancer

13 Integrated Treatment of Hepatic Cancer

14 Liver Transplantation for HepatoceUular Carcinoma

Index